Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 22;6(3):2055217320959816.
doi: 10.1177/2055217320959816. eCollection 2020 Jul-Sep.

Cannabinoid use among Americans with MS: Current trends and gaps in knowledge

Tiffany J Braley  1 , Daniel Whibley  2 , Kevin N Alschuler  3 , Dawn M Ehde  4 , Ronald D Chervin  5 , Daniel J Clauw  3 , David Williams  6 , Anna L Kratz  3
Affiliations

Cannabinoid use among Americans with MS: Current trends and gaps in knowledge

Tiffany J Braley et al. Mult Scler J Exp Transl Clin. .

Abstract

Background: Up-to-date information regarding the scope and impact of cannabinoid use among persons with MS (PwMS) is necessary to guide clinical practice and cannabinoid research.

Objectives: To assess utilization patterns and perceived impact of cannabinoid use among a national cohort of PwMS.

Methods: Data collected were part of a nationwide survey to characterize pain in PwMS. Items included questions about current/recent cannabinoid use, reasons for use, preferred THC/CBD formulations, and perceived benefits/side effects. PROMIS short-forms assessed symptom severity. Pain phenotype was assessed with the painDETECT questionnaire and FMSurvey Criteria Questionnaires.

Results: Among n = 1,027 respondents, 42% endorsed recent cannabinoid use, of which 18% endorsed healthcare provider guidance regarding use. PROMIS scores (except cognitive abilities), and pain centralization and neuropathic pain scores, were higher among recent/current users (each p < 0.0001). Sleep and pain were the most frequently reported reasons for use. Benefit from cannabinoids for sleep and pain were strongly correlated (r = 0.65, p < 0.0001). For those who expressed a preference for specific THC/CBD ratios, CBD-predominant formulations were favored.

Conclusion: Cannabinoid use is common in PwMS, despite a paucity of provider guidance. The range of perceived benefits, and potential differential effects of THC and CBD, highlight the need for personalized, evidence-based guidelines regarding cannabinoid use.

Keywords: Multiple sclerosis; cannabinoids; cannabis; insomnia; pain; sleep disturbance.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mean impact of cannabinoid use on MS symptoms (numeric rating scales).
See this image and copyright information in PMC

References

    1. O'Connor AB, Schwid SR, Herrmann DN, et al. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008; 137: 96–111. - PubMed
    1. Fiest KM, Fisk JD, Patten SB, et al. Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Mult Scler Relat Disord 2015; 4: 470–476. - PubMed
    1. Stanton BR, Barnes F, Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler 2006; 12: 481–486. - PubMed
    1. Braley TJ, Segal BM, Chervin RD. Obstructive sleep apnea and fatigue in patients with multiple sclerosis. J Clin Sleep Med 2014; 10: 155–162. - PMC - PubMed
    1. Braley TJ, Kratz AL, Kaplish N, et al. Sleep and cognitive function in multiple sclerosis. Sleep 2016; 39: 1525–1533. - PMC - PubMed

LinkOut - more resources